UNSPSC 51111728: Cabazitaxel

This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C45H57NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51F690397J. European Medicines Agency schedules cabazitaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31282. The term CABAZITAXEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60). Most nations schedule cabazitaxel under HS 29329990 and SITC 51569.

As of Q4 2014, CABAZITAXEL remains the US FDA Preferred Term for this commodity. Cabazitaxel bears US NLM identifiers UMLS ID C2830183 and NCI Concept Code C66937. SMILES: CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC.

UNSPSC 51111728 Cabazitaxel, a Commodity code, shows minimal recent state and local procurement activity directly aligned with its nominal scope. The two most recent opportunities tagged to this code do not solicit cabazitaxel or related oncology pharmaceuticals; instead, the Illinois Department of Public Health awarded a completed piggyback contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (antibiotic products), and Seminole County, Florida released an IFB for Naloxone and drug deactivation systems (emergency response supplies). State and local health departments and counties appear to be the primary issuing bodies using pharmaceutical procurement codes, but the recent record under this specific code reflects either tagging misalignment or an absence of active cabazitaxel solicitations in the current market.

Geographic activity is concentrated in Florida and Illinois based on the two recent opportunities, though this represents a very limited dataset and does not reliably characterize the code's actual demand. The Illinois Department of Public Health contract (Solicitation 26482DPHPREPDB53392, awarded August 28, 2026 for $2,999,999.11 over three years via IFB through a cooperative purchasing vehicle) and Seminole County's naloxone procurement (IFB 60459723LAS, posted June 30, 2026 with response due July 26, 2023) illustrate that state health agencies and county procurement offices do use pharmaceutical codes, but neither opportunity reflects the oncology-specific product this code nominally covers. Firms pursuing cabazitaxel or similar specialty pharmaceutical opportunities should monitor state Medicaid procurement, hospital systems, and specialty pharmacy consortia more actively than this code's recent record suggests.